摘要
目的:探讨白细胞数量稳定性对晚期非小细胞肺癌(NSCLC)患者化疗预后的影响。方法:采用前瞻性研究方法,根据化疗后白细胞计数较化疗前是否下降及下降程度,将患者分为下降且出现白细胞减少(CIL,白细胞<4.0×109 L-1)组、下降但未出现CIL组及未下降组,通过随访及统计学软件分析各组化疗有效率(RR)、疾病控制率(DCR),疾病进展时间(TTP)、总生存时间(OS)之间的差异,并确定影响预后的独立因素。结果:共入组87例患者,3组RR分别为36.3%、27.9%和13.6%(χ2=3.016,P=0.221);DCR分别为90.9%、81.4%和68.2%(χ2=3.706,P=0.157),中位TTP分别是8、7和5个月(χ2=6.119,P=0.047),中位OS分别是20、14和12个月,χ2=6.716,P=0.035。Cox多因素分析显示,CIL是影响晚期NSCLC患者生存时间的独立因素,χ2=17.589,P=0.000。结论CIL能够延长患者的疾病进展时间和生存时间,是影响晚期NSCLC患者化疗的预后的独立影响因素。
OBJECTIVE：To investigate the stability of leukocyte count with NSCLC prognosis of patients with chem- otherapy. METHODS： A prospective study,baseed on whether the extent of count of leukocyte decreased after chemo- therapy,patients were divided into three groups：decreased with CIL （chemotherapy-induced leueopenia, WBC 〈 4.0× 109 L-1）,decreased but without CIL and non-decreased. Through the follow-up and statistical software, the difference of efficiency of chemotherapy in each group were analyzed including RR （response rate）, DCR （disease control rate）, TTP （time to progression） and OS （overall survival time）,and independent prognostic factors was identified. RESULTS：Eight- y-seven patients completed the study. RR of the three groups were 36.3%,27. 9%,13. 6% （X^2=3.016,P=0.221）. DCR were 90.9% ,81.4%,68.2%（ 2 = 3. 706,P=0. 157） The median TTP were 8 months,7 months and 5 months （X^2=6.119,P=0.047）. The median suivival time were 20 months,14 months and 12 months （X^2=6.716,P=0.035）. Cox multivariate analysis showed CIL was the independent prognostic factor （X^2=17. 589, P= 0. 000）. CONCLUSION： CIL is the independent prognostic factor,which can prolong TTP and OS in patients with advanced NSCLC.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第19期1499-1502,共4页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺
药物疗法
预后
白细胞
carcinoma, non-small cell lung/drug therapy ~ prognosis
leukocytes
